文献速递淋巴瘤

晚期霍奇金淋巴瘤中根据大包块病变的存在及部位可区分出两个不同的预后组

Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease.
PubMed 文献 · Blood Adv · 2020-01-01

这项回顾性多机构研究纳入2000至2010年间814例晚期(III/IV期)霍奇金淋巴瘤患者,评估大包块病变的意义。探索队列(n=683)中最大直径与无进展生存无关联,与全因死亡率呈U形关联;以5 cm为界,纵隔大包块型较非大包块/非纵隔型总生存更优(5年OS 92% vs 86%;HR 0.53;95%CI 0.34-0.84;P=.007),并在独立验证队列(n=131)中获证实。

要点

  • 以5 cm为界,纵隔大包块型较非大包块/非纵隔型总生存更优(5年OS 92% vs 86%;HR 0.53;95%CI 0.34-0.84;P=.007)。
  • 最大直径与无进展生存无关联,与全因死亡率呈U形关联。
  • 纵隔大包块型在年龄、组织学及骨髓受累方面优于非大包块/非纵隔型(P<.001)。

核心结论

  • 晚期霍奇金淋巴瘤中,纵隔大包块与更有利的疾病特征及更优的总生存相关,可能反映更有利的生物学。

研究设计与样本

  • 回顾性、多机构研究,纳入2000至2010年间814例晚期(III/IV期)霍奇金淋巴瘤患者,探索队列n=683,独立验证队列n=131。

主要发现

  • 探索队列中最大直径与无进展生存无关联,与全因死亡率呈复杂U形关联;以5 cm为界,Kaplan-Meier分析证实该结果。
  • 纵隔大包块型在年龄、组织学及骨髓受累方面优于非大包块/非纵隔型(P<.001)。
  • 纵隔大包块型较非大包块/非纵隔型总生存更优(5年OS 92% vs 86%;HR 0.53;95%CI 0.34-0.84;P=.007)。
  • 上述发现在单纯化疗亚组中持续存在,并在独立验证队列(n=131)中得到证实。

关键数值与推荐

  • 大包块以5 cm为界值。
  • 纵隔大包块型较非大包块/非纵隔型总生存更优(5年OS 92% vs 86%;HR 0.53;95%CI 0.34-0.84;P=.007)。
  • 纵隔大包块型在年龄、组织学及骨髓受累方面优于非大包块/非纵隔型(P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Controversy exists regarding the definition and prognostic significance of bulk in advanced-stage (stage III/IV) Hodgkin lymphoma (ASHL), and bulk location (mediastinum vs other sites) further complicated the setting. This retrospective, multi-institutional study comprised 814 ASHL patients between 2000 and 2010 and aimed to evaluate the significance of bulk in ASHL. End points of interest included progression-free survival (PFS) and overall survival (OS). Covariates included maximum diameter and the site of bulky disease. SmoothHR and Kaplan-Meier analyses were used to assess for an association of PFS and OS with covariates. In the exploratory cohort (n = 683), maximum diameter had no association with PFS and a complex, U-shaped association with all-cause mortality on smoothHR analysis. Using 5 cm as a cutoff for bulk, Kaplan-Meier analyses confirmed the smoothHR results. The site of bulk was incorporated to divide patients into 2 groups. The mediastinal bulk (MB) type had more favorable characteristics than the nonbulky/non-MB (NB/NMB) type on age, histology, and bone marrow involvement (P < .001). The MB type was associated with better OS than the NB/NMB-type on univariable analysis (5-year OS, 92% vs 86%; HR, 0.53; 95% confidence interval, 0.34-0.84; P = .007). These findings persisted in the subgroup treated with chemotherapy alone and were confirmed in an independent validation cohort (n = 131). Our findings indicate that mediastinal bulk was associated with more favorable disease characteristics and improved OS in ASHL, and may be a surrogate of a more favorable biology.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Qi S, Milgrom S, Dabaja B, et al. Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. Blood Adv. 2020. PMID: 32396621. doi:10.1182/bloodadvances.2019001265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。